Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

T Cell Sciences awarded second grant for vaccine development

Feb. 11, 1997

ET antagonists reported by Japanese investigators

Feb. 11, 1997

German researchers focus on Na+/H+-exchange inhibitors

Feb. 10, 1997

Chymase inhibitors from Green Cross

Feb. 7, 1997

First Corlopam Renal Program study completed

Feb. 6, 1997

Cell migration inhibitors from Teijin

Feb. 6, 1997

Nortran completes trials in volunteers with antiarrhythmic

Feb. 5, 1997

Tanabe synthesizes ET antagonists

Feb. 5, 1997

AHP claims smooth muscle cell proliferation inhibitors

Feb. 4, 1997

Mylan Laboratories receives FDA approval for generic formulation

Jan. 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...